Latest news

• Lilly will aim for one $1bn-$5bn deal per quarter in 2020

  The Dermira deal saw Lilly gain both a marketed drug – medicated cloth Qbrexza (glycopyrronium) for uncontrolled excessive underarm sweating – as well as pipeline candidate lebrikizumab for atopic dermatitis, which is currently

• Lilly expands dermatology portfolio with $1.1bn Dermira deal

  Under the terms of the deal, Lilly will gain rights to Dermira’s single marketed drug – Qbrexza (glycopyrronium), a medicated cloth approved for use in primary axillary hyperhidrosis, or uncontrolled excessive

• AstraZeneca sells Losec rights as part of refocus strategy

  its chronic obstructive pulmonary disease (COPD) therapy PT010 (budesonide/glycopyrronium/formoterol fumarate).

• AZ builds case for its COPD triple as it chases GSK’s Trelegy

  In KRONOS, there was a 52% reduction in the rate of moderate or severe COPD exacerbations with Breztri compared with AZ’s two-drug Bevespi glycopyrronium/formoterol fumarate, and a 17% ... Breztri – which combines long-acting beta agonist (LABA)

• AZ prepares to file COPD triple, taking on rival GSK

  The KRONOS trial of PT010 – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – was presented at a medical congress ... The data